In a new investor presentation, 20/20 Biolabs (AIDX) detailed its corporate strategy, which includes a new "bolt-on" acquisition plan and its pathway to commercialize the OneTest multi-cancer early detection (MCED) test. The company is positioning OneTest to seek reimbursement under the Multi-Cancer Early Detection Screening Coverage Act, which establishes a Medicare coverage pathway for FDA-approved tests beginning in 2028.
Key Details
- M&A Strategy: The company plans to acquire or "bolt-on" companies in the health and wellness sector with $2 to $8 million in annualized revenue, targeting businesses focused on early cancer detection, longevity testing, and healthy foods.
- Path to Reimbursement: AIDX is pursuing FDA authorization and CMS coverage for OneTest, its biomarker-based MCED test. The strategy relies on a "totality-of-evidence" approach, incorporating real-world data from multiple sources.
- Real-World Evidence: Key data sources include studies with partners in Taiwan and Korea, NCI biobank samples, and a large U.S. cohort of over 35,000 firefighters expected to be tested by the end of 2026.